Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) FCF Margin (2021 - 2025)

Inmune Bio (INMB) has disclosed FCF Margin for 5 consecutive years, with 13600.0% as the latest value for Q1 2025.

  • Quarterly FCF Margin rose 3980000.0% to 13600.0% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 45836.0% through Dec 2025, up 19245686.0% year-over-year, with the annual reading at 47248.0% for FY2025, 19104486.0% up from the prior year.
  • FCF Margin hit 13600.0% in Q1 2025 for Inmune Bio, up from 53400.0% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 3002.63% in Q1 2023 to a low of 127300.0% in Q1 2021.
  • Historically, FCF Margin has averaged 25642.11% across 5 years, with a median of 9916.28% in 2023.
  • Biggest five-year swings in FCF Margin: skyrocketed 12186135bps in 2022 and later crashed -5039737bps in 2024.
  • Year by year, FCF Margin stood at 6000.0% in 2021, then grew by 2bps to 5871.13% in 2022, then crashed by -107bps to 12146.43% in 2023, then crashed by -340bps to 53400.0% in 2024, then surged by 75bps to 13600.0% in 2025.
  • Business Quant data shows FCF Margin for INMB at 13600.0% in Q1 2025, 53400.0% in Q1 2024, and 12146.43% in Q4 2023.